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Abstract
Despite many technological breakthroughs, even the best breast cancer treatments avail-
able today are not 100% effective. Chemotherapy has improved, but many drugs still 
do not reach the tumor site at effective doses and are often associated with high sys-
temic toxicity and poor pharmacokinetics. Moreover, for many malignancies, diagnosis 
is obtainable only in metastatic stages of development, reducing the overall effectiveness 
of treatment. The choice of available treatments depends on tumor characteristics such 
as biomarkers, tumor size, metastatic disease, ligands, and antigen or endocrine recep-
tor expression. Combined with surgical resection, chemotherapy and radiation remain 
the first line of treatment for patients with cancer. Even with these treatments, however, 
cancer continues to have high fatality rates and current therapeutic modalities have yet 
to significantly improve the often dismal prognosis of this disease. Nanotechnology is 
a highly focused approach, which may provide more effective and less toxic treatment 
when compared to chemotherapy. This area of research has emerged as cancer treatment 
in the form of new drugs and has reached promising results in preclinical and clinical 
trials proving its value as a potential tumor therapy.
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1. Introduction
Nanobiotechnology is defined as the biomedical application of nano-sized systems [1]. 
Nanomaterials, which measure a few nanometers in length, allow for unique interaction 
with biological systems at the molecular level. They can also facilitate important advances in 
detection, diagnosis, and treatment of human cancers and this approach is known as nano-
oncology. Breast cancer is one of the most common cancers worldwide [2]. The choice of 
available treatments depends on tumor characteristics such as biomarkers, tumor size, meta-
static disease, ligands, and antigens or endocrine receptors expression. Combined with sur-
gical resection, chemotherapy and radiation remain the first line of treatment for patients 
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with cancer [3]. Improvements have been made to chemotherapies, because drugs are still 
not reaching the tumor site at effective doses, and are often associated with high systemic 
toxicities and poor pharmacokinetics. The nanotechnology is an approach which allows more 
effective and less toxic chemotherapy.
For many malignancies, diagnosis is obtainable only during metastatic stages of develop-
ment, reducing the overall effectiveness of treatment [4]. Multidrug resistance, the principal 
mechanism by which many cancers develop resistance to drugs, is also a key factor in the 
failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and 
solid tumors, including breast cancers [5]. Triple-negative breast cancer (TNBC), with absent 
or minimal expression of estrogen and progesterone receptors, and human epidermal growth 
factor receptor 2 are most common in younger women. In later stages, the prognosis is more 
dire, when compared to that of other breast cancer subtypes, with a higher risk of relapse, 
often involving other organs [6]. Emerging nanotechnologies have exhibited the possibility of 
specifically treating or targeting breast cancer. Among nanoparticles, various lipid nanopar-
ticles, namely liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and lipid 
polymer hybrid nanoparticles, have been developed over the past few years for breast cancer 
therapy and evidence of this is documented [2].
Nanoparticles are also being actively developed for tumor imaging in vivo, biomolecular 
profiling of cancer biomarkers, and targeted drug delivery. These nanotechnology-based 
techniques can be widely applied for management of varying malignant diseases [7].
2. Breast cancer
2.1. Incidence and epidemiology
Breast cancer is the most frequent carcinoma in females and the second most common cause 
of cancer-related mortality in women worldwide. Approximately 61,000 new cases of in situ 
and 246,000 cases of invasive breast carcinoma, respectively, are expected to be diagnosed 
in the United States in 2016. Within this same period in the United States, breast cancer will 
account for an estimated 40,500 deaths among women [8]. The decline in cancer-related 
death rates over the past two decades has been driven by continued decreases in fatalities 
from breast cancer. Death rates for female breast cancer are down 36% from peak rates, 
most likely, as a result of improvements in early detection and treatment [9, 10]. By con-
trast, incidence rates increased in men for cancer of the breast. Some suggestive correla-
tions about the increased cancer rate involve changes in environmental risk factors, such as 
obesity [8, 11].
2.2. Current breast cancer diagnosis and treatment
Breast cancer diagnosis, according to the European guidelines, is based on clinical exam-
ination in combination with imaging and confirmed by pathological assessment [3]. 
Clinical examination includes manual palpation of the breasts and locoregional lymph 
nodes, along with assessment for distant metastases (bones, liver, lungs, and  neurological 
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 examination in the case of symptoms). Other forms of assessment include complete per-
sonal and family medical history, including evaluation of menopausal status, physical 
examination, blood count analysis, liver and renal function tests, and alkaline phosphatase 
and calcium checks [12].
Pathological diagnosis should be based on core-needle biopsies obtained by manual or 
preferably by ultrasound or stereotactic guidance. The pathological report should include 
the histological type, grade, estrogen receptor (ER), and for invasive cancer, progesterone 
receptor (PgR) along with human growth factor receptor type 2 (HER2) [13]. Routine stag-
ing evaluations are directed at locoregional diseases, as asymptomatic distant metastases 
are very rare and patients do not profit from comprehensive laboratory and radiological 
staging. Bilateral mammography and ultrasound of the breast and regional lymph nodes are 
included in imaging [3].
Subsequent to diagnosis, the prognostic and treatment are based on histology and immu-
nohistochemistry (IHC) data. The selection of a treatment strategy is based upon the tumor 
extent/location (size and location of primary tumor, number of lesions, and number and 
extent of lymph node involvement) and other factors such as age, lifestyle, and general health 
status of the patient [14].
Women with a high risk of breast cancer (previous chest wall irradiation for lymphoma or car-
rying the BRCA1 or BRCA2 gene mutations) may be offered risk-reducing surgery including 
prophylactic bilateral mastectomy and reconstruction [15].
Ductal carcinoma in situ may be treated with breast conservation therapy (BCT), which has 
replaced radical mastectomy as the treatment of choice for early breast cancer, providing clear 
resection margins achieve, or with mastectomy, usually followed by radiotherapy and/or che-
motherapy [16]. Whole-breast radiotherapy (WBRT) after breast-conserving surgery (BCS) 
for diagnosis of ductal carcinoma in situ (DCIS) decreases the risk of local recurrence [17]. 
Mastectomy may still be carried out based upon tumor size (relative to breast size), tumor 
multicentricity, prior radiation of the chest wall or breast, or patient choice [18]. Sentinel 
lymph node biopsy (SLNB) is now the standard of care. All modalities of chemotherapy, 
endocrine therapies (ETs), and targeted therapies as adjuvant treatments may be used preop-
eratively for patients with isolated tumor cells [13].
In HER2-positive breast cancer, trastuzumab therapy should be started in the neoadjuvant 
setting in association with the taxane part of the chemotherapy regimen. The chemotherapy 
regimens to be used in the neoadjuvant setting are the same ones used in the adjuvant setting. 
Unfortunately, there are no validated predictive markers which allow for the tailoring of the 
regimen to the individual patient. It is therefore recommended that a sequential program of 
anthracyclines and taxanes is used. ER-positive, HER2-negative carcinomas, especially of the 
lobular subtype, are generally less responsive to primary chemotherapy than ER-negative and 
HER2-positive tumors and may benefit more from primary ET. ET is usually given 4–6 months 
before surgery and continued postoperatively; for post-menopausal patients, aromatase inhibi-
tors (AIs) are more effective than tamoxifen in decreasing tumor size and require less extensive 
surgery [3, 19].
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2.3. Limitations of the current breast cancer treatments
One major challenge to the treatment of cancer is the lack of selective toxicity, which results 
in a reduced therapeutic index and, as consequence, compromises clinical prognosis. In order 
to reduce damage to normal tissues, suboptimal doses of anticancer chemotherapeutics are 
often administered [20].
Furthermore, the high interstitial fluid pressure (IFP) of solid tumors forms a barrier to trans-
capillary transport and results in poor biodistribution and penetration of drugs [21]. Another 
determinant of drug distribution within tissues is the half-life of the drugs in circulation; a drug 
with longer half-life will establish a more uniform distribution in tissues, even if its extravasa-
tion and penetration of tissues are relatively slow, whereas a drug that has a short half-life will 
have nonuniform distribution [22]. Moreover, vessels in tumor sites are heterogenic and may 
have fenestrations that increase the extravasation of drugs [23].
It has been shown that the amount of drug accumulated in normal viscera is 10- to 20-fold 
higher than that in a similarly weighted tumor site [24] and that many anticancer drugs are 
not able to penetrate more than 40–50 mm (equivalent to the combined diameter of three 
to five cells) from the vasculature [20, 25, 26]. These defects often lead to incomplete tumor 
response, multiple drug resistance (MDR), and ultimately therapeutic failure [27–29]. MDR, 
when tumor cells are treated with one anticancer drug and become resistant to a whole spec-
trum of drugs, is usually based on overexpressed drug efflux proteins and therefore is an 
important challenge for breast cancer therapy [30–33].
3. Nanobiotechnology-based platforms for breast cancer therapy
3.1. Properties of nanocarriers
The most current anticancer agents do not have an adequate job of differentiating between 
cancerous and normal cells and can lead to systemic toxicity and severe side effects. To 
overcome limitations of conventional chemotherapeutics, nanotechnology offers a more tar-
geted approach and could therefore provide significant benefits to cancer patients. The size, 
shape, and charge are important parameters in nanoparticle systems that indicate the in vivo 
distribution, targeting ability, and biological destination of nanoparticles.
Nanoparticles have many advantages over free drugs. Some of them are listed below:
• Protect the drugs from early degradation.
• Enhance absorption of the drugs into a selected tissue.
• Control the drug tissue distribution and pharmacokinetic.
• Improve intracellular penetration.
• Prevent drugs from premature interaction with the biological environment.
• Reduce systemic toxicity.
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Particles with hydrodynamic diameters below 10 nm are subject to rapid kidney clearance. 
Most of injected nanoparticles end up in the liver and spleen. Resident macrophages will 
phagocytose nanoparticles, degrade a small part of them, and exocytose both the degraded 
and intact nanoparticles. To avoid mechanical filtration by the liver and spleen, particles 
require size limitations above 200 nm [34, 35].
The zeta potential (surface charge) of nanoparticles has been shown to influence the nanopar-
ticles direction within the tumor. It has been described that positively charged nanoparticles 
show increased cell uptake and binding due to the interaction between cationic nanoparticles 
and negatively charged cell membranes. Neutral particles have demonstrated lower interaction 
with the cell membrane than those nanoparticles with the same size and charge, resulting from 
the lower number of electrostatic interactions between charged cell membranes and nanopar-
ticles surface [36–38]. In addition, studies have shown that systemically administered nanopar-
ticles, with 30–40 nm [39] and 70 nm [40] in size and having a slightly negative surface charge, 
revealed internalization by tumor cells in mice and movement away from blood vessels [38].
Neutral polymers are used to minimize nanoparticle surface charge. The polymers are gen-
erally used to reduce aggregation caused by particle-particle interactions as well as limiting 
potential electrostatically induced interactions with other components of circulation, such as 
plasma membranes of cells (negative charge). Supposing the nanoparticle surface charge is 
increased, both positively and negatively, the probability that the particle will be removed from 
circulation by macrophage increases [36, 41]. When nanomaterials are administered into the 
blood, they are taken up within minutes or by the phagocytic cells of mononuclear phagocyte 
(MPS). The opsonization can be prevented by adding poly (ethylene) glycol (PEG) to the sur-
face of nanomaterials. This addition drastically increases the blood half-life of all nanomaterials 
regardless of surface charge, improving the circulation time and accumulation in the target tis-
sue. To create long-circulating nanoparticles, a diameter between 30 and 200 nm is desired [42].
The nanoparticle surface is the site that is modified to include targeting ligands. The reason 
for including a target ligand is that the cell surface of the cognate receptor is elevated in tar-
get cancer cells relative to other cells [43]. The advantages of surface coating are that it offers 
biocompatibilities, biodistribution of the nanoparticles, and modulating interaction between 
nanoparticles and cells, tissues, and biomolecules [44].
3.2. Nanoparticle drug delivery arsenal
To construct an appropriate nanocarrier for rapid and effective clinical translation, some impor-
tant characteristics need to be considered. The nanocarriers must be made from a material that 
is biocompatible and easily functionalized along with being well characterized, soluble, exhibit 
extended circulation ability, no aggregation, and high uptake efficiency by the target cells.
Nanocarriers can be classified into three categories based upon materials that they are made 
from: (1) lipid-based, (2) polymeric, and (3) inorganic (Figure 1). These nanocarriers have been 
used for a variety of applications such as drug delivery, imaging, apoptosis detection, radia-
tion sensitizers, and photothermic ablation of tumors [7, 45, 46]. Some of these nanocarriers 
are described below.
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3.2.1. Lipid-based nanocarriers
Lipid-based drug delivery systems have attractive properties, as well as biocompatibility, bio-
degradability, and the ability to entrap both hydrophobic and hydrophilic drugs. Lipid-based 
nanocarriers include liposomes, nanoemulsion, solid lipid nanoparticles, and phospholipid 
micelles.
Liposomes were the first nanocarriers, described in 1965 by Bangham [47], and the first that 
have been clinically approved by the FDA (Food and Drug Administration) to carry che-
motherapy drugs (DaunoXome™) (50–80 nm) in 1996 [48]. Liposomes are small vesicles 
consisting of a bilayer lipid membrane surrounding an aqueous interior compartment [49]. 
The membranes consist of amphiphilic compounds, such as phospholipids and glycolipids, 
which make them biodegradable. Hydrophobic molecules are intercalated within the bilayer 
membrane, and hydrophilic molecules can be entrapped in their aqueous core, making lipo-
somes a good therapeutic carrier [50]. To improve stability and circulation half-life, liposomes 
can be coated with targeting ligands and polymers such as PEG [51]. For example, a recent 
study showed that PEG-modified liposomes of ursolic acid enhanced in vitro cytotoxicity in 
gastric cancer cells when compared to standard ursolic acid [38]. Liposomal drug formula-
tion improves the biodistribution and pharmacokinetics of a drug. This means higher drug 
Figure 1. Schematic of different kinds of nanocarriers used for drug delivery. (A) Lipid-based nanocarriers, (B) polymeric 
nanoparticles, (C) inorganics particles.
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 concentration can be achieved within tumors while reducing drug concentration in normal 
tissue [51]. Some disadvantages have been identified in the use of liposomes. Studies have 
shown that 50–80% of liposomes are adsorbed by the reticuloendothelial system (RES) and 
mainly by liver cells (Kupffer cells) within the first 15–30 min following intravenous admin-
istration [52, 53]. Other problems are related to their stability, poor batch-to-batch reproduc-
ibility, and difficulty with sterilization [54].
3.2.2. Polymeric
Polymeric nanoparticles systems are engineered from biocompatible and biodegradable poly-
mers. Polymeric nanocarriers include micelles, dendrimers, and polymer-drug conjugates.
Many biodegradable polymers have been used to produce polymeric nanoparticles such as 
poly D L-lactic-co-glycolic acid (PLGA), poly D L-lactic acid (PLA), and poly ethylene gly-
col (PEG) [55]. Polysaccharides such as chitosan, alginate, and pectin have also been used 
to encapsulate these nanostructures [56, 57]. These nanoparticles are formulated through a 
self-assembly process using block copolymers with different hydrophilicity and consisting 
of two or more polymer chains [58]. Polymeric nanoparticles have been formulated to encap-
sulate either hydrophilic or hydrophobic drugs. This system facilitates surface modifications, 
and controlled pH- dependent controlled release [59]. A recent study revealed developed 
albumin-polymer conjugate nanoparticles of curcumin and demonstrated growth inhibition 
of three-dimensional LNCaP (epithelial cell line derived from a human prostate carcinoma) 
multicellular tumor spheroids when compared to native curcumin [60]. This result is an inter-
esting option for controlled and target-based delivery.
Dendrimers are polymeric macromolecules with numerous arms extending from a center, result-
ing in a well-defined topological structure [61]. They have three main components: (1) a central 
core with two or more groups and repeated units attached to a central core called generations; 
(2) peripheral functional groups on the surface which determine the physicochemical properties 
of a dendrimer; (3) peripheral groups that can be modified to obtain both a charged hydrophilic 
and lipophilic function [62]. Dendrimers are appealing since they can be synthesized at vari-
ous sizes, molecular weights, and chemical compositions [62]. With the modification of surface 
groups, interiors, and core, the properties of dendrimers can be optimized to obtain favorable 
physical characteristics, biodistribution, and receptor-mediated targeting. Dendrimers have 
shown promise for biomedical applications because they can be easily conjugated with targeting 
molecules, are biodegradable, biocompatible, and have high water solubility [63, 64]. A success-
ful study using dendrimers was demonstrated in 2005 when methotrexate conjugated to poly-
amidoamine (PAMAM) dendrimers resulted in a 10-fold reduction in tumor size compared with 
that achieved using free systemic methotrexate [60]. In spite of promising results, dendrimers 
are relatively expensive as compared to other nanoparticles and require many repetitive steps in 
order to be synthesized, presenting a challenge for large-scale production [65].
3.2.3. Inorganic
The iron oxide nanoparticles (IO) are classified based on their sizes as standard superpara-
magnetic iron oxide (SSPIOs) at 60–150 nm, superparamagnetic iron oxide (USPIO) 5–40 nm, 
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and ultra-small and monocrystalline iron oxide (MION) 10–30 nm. Magnetic nanosystem is 
attractive due to its ability to become magnetized after exposure to a magnetic field but does 
not retain permanent magnetization once the field is turned off. These nanoparticles need to 
be small so that they can be superparamagnetic in order to avoid agglomeration after stop-
page of the magnetic field and remain in circulation without being removed by the immune 
system [36]. The IO can be degraded to Fe+ ions in the body in the acidic compartments of 
cells, for example, lysosomes, reducing the potential toxicity of nanoparticles (Figure 2). The 
magnetic flux density and permeability of exterior magnetic fields should be optimized to 
be strong enough to mediate penetration of nanoparticles across the biological barriers, and 
provide for sufficient accumulation at target sites while reducing risk to normal tissue [66, 67].
Gold nanoparticles have received attention due to their unique properties. These nanopar-
ticles are easily synthesized and size can be readily controlled by turning the synthesis pro-
cedure [68]. These nanoparticle conjugates can exhibit increased targeting rapid transport 
kinetics, long circulatory half-life, size-enhanced tumor uptake, and biocompatibility. These 
nanoparticles represent one of the most stable and easily surface functionalized for molecular 
conjugation [69]. Gold is resistant to oxidation under ambient or physiological conditions, 
which permits interaction in the biological environment. The shape of gold nanoparticles 
has been demonstrated to penetrate the cell membrane. When functionalized, they can show 
increased binding affinity and targeting selectivity with multiple targeting groups as well as 
tumor selective uptake due to their size [69].
Figure 2. Intracellular occurrence of iron oxide nanoparticles in breast cancer cells analyzed through microscopy. (A) 
Representative confocal of Raman micrographs after digital contrast enhancement in MDA-MB-231 cells. (B) Ultra-
micrographs from transmission electronic microscopic (TEM) in MCF-7 are shown. The cells were treated with 200 µM 
iron oxide nanoparticles at 37°C for 24 and 6 h, respectively. The black arrow denotes accumulation of particles in the 
cytoplasm of tumor cells.
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Inorganic nanocarriers have been used due to their physiochemical properties, such as chemi-
cal composition, size, shape, good stability, ease of functionalization, and higher surface-to-
volume ratios. Inorganic nanoparticles include gold nanoparticles, magnetic nanomaterials, 
carbon nanotubes, silica nanoparticles, and quantum dots [49].
4. Tumor targeting and uptake
4.1. Types of targeting agents
Targeting agents can be broadly classified as proteins (mainly antibodies and their fragments), 
nucleic acids, peptides, aptamers, vitamins, and carbohydrates, and they may be conjugated 
to the carriers [70]. The surface marker should be overexpressed on target cells relative to nor-
mal cells. When targeting agents are used to deliver nanocarriers to cancer cells, it is essential 
that the agent binds with high selectivity to molecules that are uniquely expressed on the cell 
surface. Nanocarriers will recognize and bind to target cells through ligand-receptor inter-
actions. The carriers are then internalized and the drug is released inside the cell [71]. The 
vitamin folic acid (folate) has also been used because folate receptors (FRs) are overexpressed 
in many tumor cells including kidney, ovarian, and endometrial cancer. The folate receptor is 
used to deliver drug conjugates to selectively accumulating drugs into cancer cell-mediated 
endocytosis [72]. One of the more commonly used ligands for cancer cells is transferrin (Tf) 
protein. Transferrin interacts with Tf receptors (TfRs), which are overexpressed in a range 
of tumor cells including lung, colon, pancreatic, and bladder cancers to increased metabolic 
rates [73]. Tf receptors binding directly to nanoparticles such as liposomes have resulted in 
improved intracellular delivery and therapeutic outcomes in animal tumor models [65, 74, 
75]. Studies show that Tf is also used to facilitate small interfering RNAs (siRNA) delivery 
through transferrin receptors, allowing for antitumor activity [76]. Targeting receptors whose 
expression correlates with metabolic rate, such as folate and Tf, are also expressed in fast-
growing healthy cells such as endothelial, epithelial, and fibroblasts cells, and this could lead 
to non-specific targeting and may increase toxicity and decrease drug efficiency [77].
4.2. Passive nanoparticle target
Nanoparticles circulating in the bloodstream can reach the neoplastic tissue by passive drug 
targeting through the enhanced permeation and retention effect (EPR) (Figure 3) [45, 78]. 
When a solid tumor reaches a certain size, the normal vasculature present in its early stage is 
not sufficient enough to provide the oxygen required for proliferation [79]. Because of this, the 
cells start to die and they secrete growth factors, which trigger angiogenesis, where budding 
of new blood vessels from the surrounding capillaries occurs, increasing their permeability. 
Angiogenesis in tumors is the process of rapid development of new, irregular blood vessels 
that present a discontinuous epithelium and lack the basal membrane of normal vascular 
structures [80, 81]. Fenestrations in the capillaries, depending on the location and tumor type, 
can reach sizes from 200 to 2000 nm. The fenestrations between endothelial cells facilitate the 
extravasation of nanocarriers from the surrounding vessels into the tumor [82]. The extracel-
lular fluids are constantly drained into the lymphatic vessels, and this allows for the renewal 
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of interstitial fluid and the recycling of extravagated solutes and colloids back to the circula-
tion [83]. In tumors, the lymphatic function is defective and, consequently, the uptake of the 
interstitial fluid is minimal [84]. Free drugs may diffuse nonspecifically and a nanocarrier 
can extravasate into the leaky vessels of tumor tissues through the EPR effect. A study using 
liposomes of different sizes suggests that particles with a diameter of 200–300 nm are able to 
extravasate, whereas in another part of the same tumor, molecules only a few nanometers in 
size may have difficulty entering the interstitium [85]. The success of EPR effect depends on 
factors such as lymphatic drainage rate, blood flow that is different in various tumor types 
and degrees of capillary disorder.
4.3. Active nanoparticle target
Passive targeting is available only in certain types of tumors and does not, necessarily, 
insure internalization of nanocarriers by targeted cells. Nanocarriers can be engineered 
to attach targeting with selective agents to employ active targeting [86]. As previously 
described in topic 4.1, some of these agents include peptides [87], proteins [88], antibodies 
[89], and small organic molecules [90–92]. These agents are complementary to receptors 
that are overexpressed or present in tumor cells [93]. The objective of passive targeting is 
to increase interactions between nanoparticles and cells and to enhance internalization of 
drugs without altering biodistribution [94, 95]. Some physicochemical properties might also 
affect the efficacy of active targeting in vitro and in vivo. These properties, such as the size of 
nanoparticles [96], choice of the targeting ligand [97], and ligand density [98] may affect the 
efficacy of the active targeting of nanoparticles. The nonspecific biding of proteins during 
Figure 3. Schematic representation showing enhanced permeability and retention of nanoparticles in tumor.
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the nanoparticles dislocation through the blood stream and the administration route has 
been shown to affect the targeting ability of nanocarriers [99]. Active targeting can be used 
for controlled drug release applications, where the drug is released into the extracellular or 
intracellular environment. The targeting agents can be used to facilitate nanocarrier inter-
nalization into cells, primarily via endocytosis (Figure 4) [100].
5. Nanocarriers and multidrug resistance
Multidrug resistance (MDR) limits the potency of many chemotherapeutics can be classified 
into two types: acquired MDR that can be developed during traditional chemotherapy in 
common doses and intrinsic MDR that can be developed from preexisting resistance pres-
ent in tumor cells. MDR is the decreased cell uptake and increased efflux of a drug. MDR 
transporters carry a variety of anticancer drugs out of cancer cells reducing the intracellular 
drug doses and produce resistance to chemotherapy [101]. If there is tumor recurrence, che-
motherapy may fail because of residual drug-resistant cells dominating the tumor popula-
tion [5]. Chemotherapy will kill only drug-sensitive cells that do not, or only mildly, express 
MDR transporters, leaving behind drug-resistant cells that overexpress MDR transporters. 
The main drug efflux transporters include P-glycoprotein (MDR1 or ABCB1), multidrug 
resistance-associated proteins (MRP1 or ABCC1), and the breast cancer resistance protein 
(ABCG2) [102–104]. To combat MDR, stimuli-responsive multifunctional nanoparticle-based 
drug delivery systems, which can deliver drugs into cells, release the drug in a specific site or 
Figure 4. Cellular uptake mechanism. The ligand-coated nanoparticle binds to the membrane receptor, enters the cells 
by primary endosome, and then forms an acidified endosome. The enzymatic digestion of nanoparticles is done by 
fusion of lysosomes.
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at a specific time. To overcome MDR, an optimal drug delivery system has to release drugs 
into cytoplasm rapidly and completely, leading to sufficiently high intracellular drug con-
centration to exceed drug efflux and limit concentration, in order to inhibit the proliferation 
of drug-resistant cancer cells and kill them. A study done using non-ionic copolymer with 
a hydrophobic core containing doxorubicin, called SP1049C, has been shown to circumvent 
p-glycoprotein-mediated drug resistance. The study was done on a mouse model of leukemia 
and it is currently in clinical evaluation. This study demonstrated the possibility of using 
nanocarriers to bypass MDR transporters [102, 105–107].
6. Preclinical and clinical trials for nanoparticles breast cancer therapy
The nanomedicine industry perspective toward oncology-based nanomedicinal therapeutics 
is very promising. The aim of these compounds to improve the therapeutic index of antican-
cer drugs by modifying their pharmacokinetics and tissue distribution to improve delivery to 
the site of action is well known and has also been demonstrated clinically. The first anticancer 
nanomedicine approved by the FDA in 1995, Doxil™/Caelyx™ [108], achieves a differential 
distribution of doxorubicin versus the free drug and is now approved for several applications, 
including breast cancer, based upon improved safety with equivalent or superior efficacy 
versus standard therapies.
Nanomedicines for breast cancer therapy or diagnosis in clinical development can be broadly 
divided into five main types: liposomes, polymeric conjugates, polymeric nanoparticles, poly-
meric micelles, and others. Examples of marketed anti-breast cancer nanomedicines and those 
in clinical development are summarized in Table 1.
Nanomedicine type Drug Product name/company Indication Phase
Liposomes Doxorubicin Myocettm/Teva UK Metastatic Breast Cancer Approved
Paclitaxel LEP—ETU/Insys Breast cancer Phase II
EndoTAG-1/MediGene Breast cancer Phase II
Polymeric conjugates Irinotecan NKTR102 (PEG)/Nektar Metastatic breast cancer Phase III
Polymeric micelles Paclitaxel Genexol-PM™/Samyang 
Biopharmaceuticals
Breast cancer Approved
Docetaxel Genexol-PM™/Samyang 
Biopharmaceuticals
Breast cancer (NSCLC, 
prostate, ovarian, head and 
neck, gastric, and esophageal 
cancer)
Marketed in 
South Korea
Paclitaxel NK105/NanoCarrier™ Breast cancer Phase III
Other Paclitaxel Abraxane ™/Celgene Advanced breast cancer Approved
Phospholipid 
stabilized 
microbubble
SonoVue/Bracco Imaging Ultrasound enhancement for 
breast and other cancers
Approved
Table 1. Clinically and preclinical nanoparticle for breast cancer therapies and diagnostics, grouped by their trial phases.
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7. Conclusions
The choice of appropriate nanocarriers is a difficult one. It is important to understand the key 
nanoparticle features such as properties, size, targeting ligand, and charge to improve the 
design for oncology applications. Nanoparticle therapeutics has been used for many treat-
ments of most cancers. Although the field of nanomedicine is developing rapidly, there are 
still a limited number of nanocarriers approved by the FDA and limited available clinical 
data. More clinical trials are required to better understand the advantages and disadvantages 
of nanoparticle therapeutics. Well-designed studies are important for development of these 
drugs. Further research is needed to develop new nanotherapeutics incorporating a variety 
of characteristics along with good experimental design in order to achieve improvements in 
treatments and nanoparticle targeting to overcome current limitations.
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